2025
Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Gueorguieva R. Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial. International Journal Of Eating Disorders 2025 PMID: 40631364, PMCID: PMC12268943, DOI: 10.1002/eat.24502.Peer-Reviewed Original ResearchCognitive-behavioral therapyOvervaluation of shape/weightDifferential treatment responseRandomized Controlled TrialsBinge-eating disorderCognitive-behavioralDelay discountingBinge eatingPosttreatment assessmentLisdexamfetamineTreatment responseSecondary outcomesControlled TrialsTreatment effectsIndividualized treatmentBinge-eatingShape/weightBingePrimary outcomeEatingSignificant improvementDisordersMetabolic variablesPosttreatmentSignificant effectThe effect of inpatient brief cognitive-behavioral therapy for suicide prevention on post-discharge emergency department utilization: Secondary analysis of a randomized clinical trial
Diefenbach G, Collett S, Black S, Rudd M, Gueorguieva R, Tolin D. The effect of inpatient brief cognitive-behavioral therapy for suicide prevention on post-discharge emergency department utilization: Secondary analysis of a randomized clinical trial. General Hospital Psychiatry 2025, 93: 73-79. PMID: 39837259, DOI: 10.1016/j.genhosppsych.2025.01.007.Peer-Reviewed Original ResearchConceptsSubstance use disordersBrief cognitive-behavioral therapyCognitive-behavioral therapyED visitsSuicide preventionSecondary analysisEmergency departmentSuicide-related ED visitsHistory of suicide attemptsEmergency department utilizationElectronic medical record reviewPost-discharge emergency departmentMedical record reviewED utilizationPsychiatric readmissionTreatment effectsSuicide attemptsUse disorderRecord reviewSelf-ReportRandomized clinical trialsGeneralized linear modelVisitsSuicidePost-discharge ED visits
2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024, 182: 209-218. PMID: 39659158, PMCID: PMC11786997, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized Controlled TrialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled TrialsDisordersPosttreatmentIndividualized treatmentMixed modelsLisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply